Laura Buyan Dent

Dr. Laura Buyan Dent

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Book Chapter
Closed access
MRMartina Rafanelli
Martina Rafanelli
KWKathleen Walsh
Kathleen Walsh
MHMohamed H Hamdan
Mohamed H Hamdan
LDLaura Buyan Dent
Laura Buyan Dent

6 June 2025 in Brain Stimulation
Verified
Journal Article
Open access
CLCuong Luu
Cuong Luu
JRJordan Ranum
Jordan Ranum
YYYoungwon Youn
Youngwon Youn
JPJennifer L. Perrault
Jennifer L. Perrault
BKBryan M. Krause
Bryan M. Krause
ASAaron J. Suminski
Aaron J. Suminski
Essential tremor (ET), the most common movement disorder in adults, presents with involuntary shaking of the upper extremities during postural hold and kinetic tasks linked to dysfunction in the cerebello-thalamo-cortical network. Recently, transcutaneous afferent patterned stimulation (TAPS), applied through a wrist-worn device, has emerged as a non-invasive treatment for medication-refractory ET. However, its mechanism remains unclear. We hypothesize that TAPS reduces tremors through modulation of the VIM thalamus in the cerebello-thalamo-cortical network. Employing refractory pure ET patients seeking VIM deep brain stimulation (DBS), we quantified clinical tremor improvement following TAPS treatment in a pre-operative setting, followed by intra-operative microelectrode recording of the contralateral thalamus with concurrent TAPS treatment on and off. After one preoperative session, TAPS significantly reduces upper limb tremor average (0.61, p = 0.002), with an asymmetric effect favoring the treated limb (p = 0.047) and the greatest improvement tending to kinetic tremor (R2 = 0.943, p = 0.002). The magnitude of TAPS-related tremor reduction demonstrates a positive correlation with the modulation of alpha (R2 = 0.213, p < 0.001) and beta band LFPs (R2 = 0.255, p < 0.001) in the VIM. TAPS also suppressed spiking activity in the VIM (R2 = 0.104, p = 0.029), though it was uncorrelated with the degree of tremor reduction. Of note, TAPS-related modulation of LFPs and spiking activity was greatest near the optimal placement location for the DBS lead in treating ET (R2 = 0.122, p = 0.006). In sum, TAPS likely reduces tremor in ET by modulating the VIM and connected nodes in the cerebello-thalamo-cortical pathway.

3 October 2021
Verified
Book Chapter
Closed access
PDF file
LDLaura Buyan Dent
Laura Buyan Dent
KSKathleen M. Shannon
Kathleen M. Shannon

20 July 2026 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
PDF file
CLCuong P. Luu
Cuong P. Luu
JPJennifer L. Perrault
Jennifer L. Perrault
AGAayush Goud
Aayush Goud
LKLionel Fotso Kamga
Lionel Fotso Kamga
JRJordan N. Ranum
Jordan N. Ranum
WLWendell B. Lake
Wendell B. Lake
BACKGROUND: Medication-refractory essential tremor (ET) patients who undergo MR-guided focused ultrasound or Gamma Knife thalamotomy may experience tremor recurrence, prompting rescue deep brain stimulation (DBS). Yet, the impact of prior ventral intermediate nucleus (VIM) lesioning on DBS targeting, microelectrode recording (MER), and stimulation programming remains uncertain. OBSERVATIONS: The authors present 3 ET patients undergoing bilateral DBS for tremor recurrence after thalamotomy. Thalamotomy lesions showed depressed electrophysiological activity versus nonlesioned VIM on MER (p = 0.0397) and required smaller DBS charge density increases for tremor control, suggesting irreversible lesion effects despite tremor recurrence. Tremor recurrence correlated with lesion mislocation; specifically, ablations missed the central VIM (mean 1.8 mm) and decussating dentato-rubro-thalamic tract. For rescue DBS, ventral VIM stimulation yields the greatest tremor reduction, while central VIM stimulation balanced tremor control with adverse effects. LESSONS: DBS is a safe, effective rescue treatment for failed thalamotomy without needing to retarget the prior lesion site. The authors advocate for prospective studies of initial DBS targeting 2 mm anterior to standard VIM coordinates, reducing intraoperative readjustment for central VIM stimulation; and initial thalamotomy targeting 1 mm anterior and 1.2–1.5 mm superior to standard coordinates for durable tremor control through ablation of both central and ventral VIM. https://thejns.org/doi/10.3171/CASE25955

23 September 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
CGCatherine L. Gallagher
Catherine L. Gallagher
MHMaureen Haebig
Maureen Haebig
AHAnanya Heroor
Ananya Heroor
RTRachna Tiwari
Rachna Tiwari
DPDavid T. Plante
David T. Plante
KPKristen A. Pickett
Kristen A. Pickett

LDLaura Buyan Dent
Laura Buyan Dent
Parkinson disease (PD) and mood disorders represent two substantial global health burdens that increasingly co-occur as both conditions rise in prevalence worldwide. Diagnosing Parkinson disease in patients with pre-existing mood disorders is clinically challenging due to overlapping symptoms, medication effects, and shared neurobiological mechanisms. Apathy, psychomotor slowing, and fatigue may mimic depressive symptoms, leading to delayed recognition of early parkinsonism. Development of an underlying neurodegenerative disorder could account for some treatment-resistant symptoms or treatment failures if not recognized. Therefore, the identification of PD will change the treatment and management plan significantly. Accurate diagnosis of PD requires a detailed neurologic examination focusing on bradykinesia, rigidity, and resting tremor, supported when appropriate by dopamine transporter imaging (DaT scan) or other emerging biomarkers. Understanding the temporal relationship between psychiatric and motor features helps differentiate prodromal PD from primary mood disorders. Management of patients with both mood disorders and PD integrates dopaminergic replacement therapy for motor symptoms with individualized treatment of psychiatric comorbidities. Levodopa remains the cornerstone for motor control, while dopamine agonists, MAO-B inhibitors, and COMT inhibitors can be added as needed. For depression and anxiety, SSRIs and SNRIs are first-line choices; quetiapine or clozapine are preferred when treatment for psychosis is necessary. Intentional, thoughtful polypharmacy is frequently required. Non-pharmacologic interventions—including cognitive behavioral therapy, structured exercise, and patient–caregiver education—enhance mood, function, and quality of life. Multidisciplinary collaboration between neurology, psychiatry, and allied health professionals is essential for optimal outcomes. This review offers guidance to healthcare providers as well as other interested parties involved in patients with mood disorders who may also be developing or have PD, especially to those who may have limited access to neurologic resources.